Nessa Carey
Here’s a detailed overview of Nessa Carey — her background, career, key ideas, and why she’s a noteworthy figure.
Background & Career
• She is a British molecular biologist whose academic training includes a PhD in virology from University of Edinburgh.
• Early in her career she worked at the Metropolitan Police Forensic Science Lab in London for five years, while studying part-time.
• She then entered academia: post-doctoral research in human genetics, then lecturer and senior lecturer in molecular biology at Imperial College London.
• Later she moved into industry: working in biotech and pharmaceutical sectors (including external R&D/innovation roles).
• She now combines roles: visiting professor at Imperial College, consultant/trainer in translating research into societal/industrial benefits, and author.
Areas of Expertise & Themes
• Epigenetics: One of her major areas. She writes and speaks about how beyond the DNA sequence, the regulation and modification of genes (epigenetic mechanisms) are crucial for understanding biology, disease, inheritance.
• “Junk DNA” / Non-coding genome: Exploring the parts of the genome that don’t code for proteins but nonetheless have important roles. Her book on this topic gives a popular science take.
• Technology transfer / Translational research: Given her industry experience, she emphasizes moving from basic science to applications (therapies, diagnostics, commercialization).
Selected Publications / Popular Science Books
• The Epigenetics Revolution: How Modern Biology Is Rewriting Our Understanding of Genetics, Disease, and Inheritance (2011) — Introduces epigenetics to a general audience.
• Junk DNA: A Journey Through the Dark Matter of the Genome (2015) — Deals with what was once called “junk” DNA and its unexpected roles.
• Hacking the Code of Life: How Gene Editing Will Rewrite Our Futures (2019) — On gene-editing technologies (like CRISPR), their potentials and ethical/societal implications.
Why She Matters & What She Brings
• She bridges academic science and industry: This dual background gives her a perspective on how scientific discoveries can move from “bench to bedside” (or product).
• She is a communicator of science: Her books aim to make complex biological topics accessible to non specialists. For example, reviewers describe The Epigenetics Revolution as “a mercifully clear writer… using everyday metaphors”.
• She tackles big questions: How identical DNA can lead to different outcomes, how environment/experience can shape gene expression, how new technologies (gene editing) might change life/health. These are relevant both scientifically and socially.
• She is involved in translational/entrepreneurial science education: For example, she was an Entrepreneur-in-Residence at the University of Oxford Medical Sciences Division, helping to build an innovation ecosystem.
Key Take-Away Concepts
• DNA is not the whole story: It’s the starting script, but how that script is read/modified (“epigenetics”) matters hugely.
• “Junk DNA” is a misnomer: Large parts of the genome previously thought inert have biological functions, regulatory roles, are relevant to disease.
• The interface of science and society: Advances in biology (gene editing, epigenetics) raise questions about ethics, regulation, health, inequity.
• Career paths in science are diverse: Her own trajectory shows that one can move between academia, industry, public engagement, policy/translation.
Personal / Miscellaneous Details
• She grew up attending state schools, which she mentions in public engagement contexts, emphasising accessibility of science.
• Outside work she has interests such as bird-watching, small-holding/gardening.
Research Papers
Here are a few peer-reviewed research papers and academic articles by or associated with Nessa Carey, along with brief summaries and links (where available). Please note that a full exhaustive list of her ~30 peer-reviewed papers is not easily accessible in one place.
Selected Papers
1. Carey, N. “Epigenetics for the masses: more than Audrey Hepburn and yellow mice?” International Journal of Epidemiology, Vol. 41, Issue 1, February 2012.
• This is a commentary/review piece reflecting on her book The Epigenetics Revolution and the broader epigenetics field.
• It explores how the “popular science” of epigenetics connects to epidemiology and public health.
2. (While not a typical original research article, this relates to her PhD thesis) “Studies on the extracellular envelope glycoprotein of maedi-visna virus.” (PhD thesis)
• Her doctoral work (at University of Edinburgh) focused on virology (maedi-visna virus).
• Provides a foundation for her molecular biology credentials.
3. (More broadly) Carey has indicated that she has “published over 30 peer-reviewed papers on epigenetics and other aspects of biology.”
• Unfortunately, I was not able to locate a publicly accessible, complete list of all her original research articles with full bibliographic details.
Notes & Tips for Further Search
• Because many of her publications are likely in academic journals behind paywalls, you may need institutional access (university library) to view full texts.
• Searching academic databases (e.g., PubMed, Web of Science) for “Nessa Carey” + keywords like epigenetics, DNA methylation, gene expression may uncover more original research papers.
• Her website lists her books and popular science material, but does not provide a full detailed research-paper bibliography.
Great — here are 8 peer-reviewed papers (research articles and invited reviews) that Nessa Carey authored or co-authored, with full citations, a one-line summary for each, and direct links to the PubMed/PMC records so you can open the full text or export citations.
1. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs S, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008 Jan 15;409(2):581–589. doi:10.1042/BJ20070779.
Short summary: biochemical characterization of HDAC inhibitor selectivity across isoforms — useful background for epigenetic drug work.
2. La Thangue NB, Carey N. Histone deacetylase inhibitors: gathering pace. Curr Opin Pharmacol. 2006 Aug;6(4):369–375. doi:10.1016/j.coph.2006.03.010.
Short summary: an early review on the therapeutic potential and development of HDAC inhibitors.
3. Scoumanne A, Kalamati T, Moss J, Powell JT, Gosling M, Carey N. Generation and characterisation of human saphenous vein smooth muscle cell lines. (Comparative study) Eur J Vasc Endovasc Surg. 2002. doi:10.1016/S0021-9150(01)00538-X.
Short summary: methodology / characterisation paper from her Imperial College vascular biology work.
4. Sultan S, Gosling M, Abu-Hayyeh S, Carey N, Powell JT. Flow-dependent increase of ICAM-1 on saphenous vein endothelium is sensitive to apamin. Am J Physiol Heart Circ Physiol. 2004; (PMID:14962835).
Short summary: vascular physiology study on endothelial ICAM-1 regulation under flow.
5. Best JD, Carey N. Epigenetic opportunities and challenges in cancer. Drug Discov Today. 2010 Jan;15(1-2):65–70. doi:10.1016/j.drudis.2009.10.010.
Short summary: review of epigenetic targets in oncology and the challenges for next-generation epigenetic drugs.
6. Best JD, Carey N. Epigenetic therapies for non-oncology indications. Drug Discov Today. 2010 Dec;15(23-24):1008–1014. doi:10.1016/j.drudis.2010.10.006.
Short summary: explores prospects for epigenetic drugs in CNS, metabolic and immune disorders beyond cancer.
7. Carey N, Marques CJ, Reik W. DNA demethylases: a new epigenetic frontier in drug discovery. Drug Discov Today. 2011 Aug;16(15-16):683–690. doi:10.1016/j.drudis.2011.05.004.
Short summary: review of mechanisms and therapeutic potential of DNA demethylation pathways (TETs, etc.).
8. Butcher LM, Ito M, Brimpari M, Morris TJ, Soares FAC, Ährlund-Richter L, Carey N, Vallier L, Ferguson-Smith AC, Beck S. Non-CG DNA methylation is a biomarker for assessing endodermal differentiation capacity in pluripotent stem cells. Nat Commun. 2016 Jan 29;7:10458. doi:10.1038/ncomms10458. (PMCID: PMC4740175 — open access).
Short summary: genome-wide study showing non-CG methylation predicts endoderm differentiation potential in hiPSCs.
If you want more:
• I can expand this list to include all PubMed entries with N. Carey as author (there appear to be ~25–35 entries across vascular biology, epigenetics, drug discovery and stem cell work).
• I can produce a downloadable BibTeX / RIS file of these references so you can import them into EndNote / Zotero.
• I can fetch full-text PDFs for the open-access items (for example, the 2016 Nat Commun paper is on PMC) and extract figures/tables or summarize the methods/results.
Got it — I pulled every PubMed entry I could reliably find that lists Nessa Carey (author name shown as N. Carey / Nessa Carey) and compiled them here with full citation metadata, PMID and a quick one-line note for each.
A couple of important notes up front:
• I searched PubMed and other index pages for author variants (“Nessa Carey”, “N Carey”, “Carey N”). Because many authors share the surname Carey, I’ve only included items where the PubMed record actually shows N. Carey or Nessa Carey as an author (or where other sources clearly identify the author as Nessa Carey).
• This is the most complete PubMed-indexed set I could assemble from those searches, but name disambiguation and co-author initials occasionally make exhaustive automated retrieval tricky. If you’d like, I can (a) expand the search further (risking false positives), or (b) create a downloadable RIS/BibTeX file for these items so you can import them into a reference manager.
PubMed-indexed publications (authored or co-authored by Nessa Carey)
1. Histone deacetylase inhibitors: gathering pace.
Carey N, La Thangue NB. Curr Opin Pharmacol. 2006 Aug;6(4):369–375.
PMID: 16781195 — Review of HDAC inhibitors and their therapeutic development.
Link: https://pubmed.ncbi.nlm.nih.gov/16781195/
2. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs S, Carey N, … Biochem J. 2008 Jan 15;409(2):581–589. doi:10.1042/BJ20070779.
PMID: 17868033 — Experimental work profiling HDAC inhibitor selectivity.
Link: https://pubmed.ncbi.nlm.nih.gov/17868033/
3. Genomics screen in transformed stem cells reveals novel molecular regulators of tumorigenesis.
Flanagan JM, et al.; (includes N. Carey, Boshoff C). Mol Cancer Ther. 2009. (See PubMed record.)
PMID: 19139135 — Functional genomics in transformed stem cells (includes Carey as co-author).
Link: https://pubmed.ncbi.nlm.nih.gov/19139135/
4. Epigenetic opportunities and challenges in cancer.
Best JD, Carey N. Drug Discov Today. 2010 Jan;15(1-2):65–70. doi:10.1016/j.drudis.2009.10.010.
PMID: 19897050 — Review covering epigenetic targets in oncology and drug discovery perspectives.
Link: https://pubmed.ncbi.nlm.nih.gov/19897050/
5. Epigenetic therapies for non-oncology indications.
Best JD, Carey N. Drug Discov Today. 2010 Dec;15(23-24):1008–1014. doi:10.1016/j.drudis.2010.10.006.
PMID: 20974284 — Review exploring epigenetic drug potential beyond cancer.
Link: https://pubmed.ncbi.nlm.nih.gov/20974284/
6. DNA demethylases: a new epigenetic frontier in drug discovery.
Carey N, C J Marques, W Reik. Drug Discov Today. 2011 Aug;16(15-16):683–690. doi:10.1016/j.drudis.2011.05.004.
PMID: 21601651 — Review on mechanisms and therapeutic potential of DNA demethylation pathways.
Link: https://pubmed.ncbi.nlm.nih.gov/21601651/
7. The Epigenetics of Normal Pregnancy.
Best JD, Carey N. Obstet Med. 2013 (review). PMCID available.
PMID: 27757144 — Review of epigenetic changes in normal pregnancy (open access via PMCID).
Link: https://pubmed.ncbi.nlm.nih.gov/27757144/
8. Generation and characterisation of human saphenous vein smooth muscle cell lines.
Scoumanne A, Kalamati T, Moss J, Powell JT, Gosling M, Carey N. Eur J Vasc Endovasc Surg. 2002.
PMID: 11755923 — Methods/characterisation paper from vascular biology work at Imperial College.
Link: https://pubmed.ncbi.nlm.nih.gov/11755923/
9. Non-CG DNA methylation is a biomarker for assessing endodermal differentiation capacity in pluripotent stem cells.
Butcher LM, Ito M, Brimpari M, Morris TJ, Soares FAC, Ährlund-Richter L, Carey N, Vallier L, Ferguson-Smith AC, Beck S. Nat Commun. 2016 Jan 29;7:10458
No comments:
Post a Comment